ResMed Inc.ASX: RMDStrong business outlook contrasts with fading technical momentum, keeping near-term downside risks elevated.Stock Performance Profile: (Source: TradingView) 3-Month Performance Profile of RMD on a DTF compared to S&P/ASX 200 (XJO). ResMed delivered a strong FY26, with revenue increasing 8% to US$5.7 billion, non-GAAP EPS rising 16% to US$11.17 and free cash flow
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
